SPHK1 and prostate carcinoma: As shown, in the pCan-2 primary prostate cancer cells and established lines (PC-3 and LNCaP), the SphK1/2 dual inhibitor induced significant apoptosis activation, evidenced by significantly increased TUNEL-positive nuclei ratio (Fig. 3G).